Treatment for Grade 1 Benign Prostatic Hyperplasia (BPH)
Initial Management Approach
- The American Urological Association recommends watchful waiting for patients with mild symptoms (Grade 1 BPH) and for patients with moderate to severe symptoms who are not bothered by them 1, 2
- Watchful waiting involves monitoring the patient without active intervention for BPH 2
- Patients with mild symptoms (AUA Symptom Score <7) should be managed using watchful waiting 1
- Patients with moderate or severe symptoms (AUA Symptom Score >8) who are not bothered by their symptoms should also be managed with watchful waiting 1
- During watchful waiting, patients are typically reexamined yearly, repeating the initial evaluation 2
Lifestyle Modifications During Watchful Waiting
- Symptom distress may be reduced with simple measures such as decreasing fluid intake at bedtime 2
- Decreasing caffeine and alcohol intake can also help reduce symptom distress 2
- Implementing other behavioral modifications to reduce symptom impact can be beneficial 1
When to Consider Medical Therapy
- Medical therapy may be considered if symptoms progress and become bothersome 1
- The patient has demonstrable prostatic enlargement 3, 4
- The patient wishes to reduce risk of disease progression 3
Medical Treatment Options
Alpha-Adrenergic Blockers
- Alpha blockers are first-line drugs for symptomatic BPH when medical therapy is indicated 5
- Options include alfuzosin, doxazosin, tamsulosin, and terazosin 5
- These medications work by inhibiting alpha1-adrenergic-mediated contraction of prostatic smooth muscle 5
- Alpha blockers usually provide an average 4-6 point improvement in the AUA Symptom Index 5
- Common side effects include orthostatic hypotension, dizziness, tiredness, ejaculatory problems, and nasal congestion 5
5-Alpha-Reductase Inhibitors
- Finasteride and dutasteride are appropriate for patients with LUTS associated with demonstrable prostatic enlargement 3
- These medications are ineffective in patients who do not have enlarged prostates 3, 4
- Finasteride reduces prostate size by 15-25% within 6 months 6
- Patients experience an average 3-point improvement in symptom scores 3, 4
- Side effects are primarily sexually related (decreased libido, ejaculatory dysfunction) 3
- Finasteride reduces the risk of acute urinary retention and the need for BPH-related surgery 3
Common Pitfalls to Avoid
- Initiating medical therapy for patients with mild symptoms who are not bothered by them 1
- Using 5-alpha-reductase inhibitors in patients without prostatic enlargement 3, 4
- Failing to adjust PSA interpretation in patients on finasteride (PSA decreases by approximately 50%) 4
When to Consider Referral to Urology
- Development of complications such as renal insufficiency, urinary retention, or recurrent infections 7